⚕ GalenOps field
←

SITE015-0023

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-03-20

AEs
7
Serious
2
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-12 (study day 46); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-25 (study day 120); relationship: not assessed

severe serious assessed

Grade 4 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-09-05 (study day 162); relationship: not assessed; serious criteria: life-threatening

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-06 (study day 163); relationship: Y

severe serious assessed

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 226); relationship: Y; serious criteria: hospitalization

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 309); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-11 (study day 321); relationship: not assessed

Data queries

No data queries.